You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Trading
Institutions
Fees
Promotions
FAQ
Education
Download
About us
Hong Kong
uSMART
EN
Login/Register
Market News

Market News

HomeMarket NewsDetails

賽生藥業(06600.HK)那西妥單抗上市申請獲納入優先評審

阿思達克 09-11 13:43
賽生藥業(06600.HK)公佈，中國國家藥監局已受予DANYELZA(那西妥單抗)生物製品許可申請的優先評審資格，適應症爲復發╱難治性高危神經母細胞瘤。 2020年12月，公司與Y-mAbs達成獨家無限期授權許可協議，成爲DANYELZA及omburtamab於大中華的獨家共同開發及商業化夥伴。
赛生药业(06600.HK)
Relevant Stocks
赛生药业(06600.HK)
Relevant Recommendation
Business Collaboration
Account Opening

Services

FeesFAQExclusive Trading Tools

About Us

OverviewContact UsMedia Center

Agreement Statement

DisclaimerPrivacy Statement
Contact Us
Customer Service Hotline︰+852 3018 4526
Email︰cs@usmarthk.com
Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong
WhatsApp︰+852 5989 2641
Join the Community：
uSMART-Facebook-Page
uSmart Securities Limited
is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Copyright © 2022 uSMART . All Rights Reserved.